GlassScriptPhysician profile
Prakash Kandel
NPI 1255619052
$598.61
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $36.34 · 2021: $120 · 2022: $222.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.06 | 2019-2022 | |
| Ptc Therapeutics, INC. | $127.59 | 2022 | |
| Janssen Pharmaceuticals, INC | $64.35 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $55.13 | 2019-2021 | |
| Gilead Sciences, INC. | $41.27 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $22.22 | 2019 | |
| Advanced Respiratory, INC | $20.92 | 2019 | |
| Biomerieux INC | $17.59 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $17.22 | 2019 | |
| Merck Sharp & Dohme LLC | $14.26 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prakash Kandel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.